Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

Horizon Therapeutics Plc presented positive new MRI data from the phase 3 clinical trial of UPLIZNA (inebilizumab) at the 9th Congress of the European Academy of Neurology (EAN) in Budapest ...

Uplizna is currently approved in the U.S. for ... Amgen (AMGN) also released results from a Phase 3 study called HORIZON for ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of Daily Living score compared to placebo at week 26. Results from the Phase III ...

Rare disease drugs like Tepezza, Krystexxa and Uplizna, added from last year’s acquisition of Horizon Therapeutics, are also boosting top-line growth. Amgen is also evaluating Kyprolis ...

72.3% of AChR+ patients on Uplizna saw a ≥3-point MG-ADL score improvement vs. 45.2% on placebo. Uplizna is under FDA priority review for IgG4-related disease with a PDUFA date of April 3.

(RTTNews) - Amgen Inc. (AMGN) Thursday announced positive data from the Phase 3 MINT study of Uplizna in adults with generalized myasthenia gravis (gMG). Myasthenia gravis is a chronic autoimmune ...

Uplizna is part of Amgen’s rare disease franchise and was added to its portfolio following the acquisition of Horizon Therapeutics for nearly $28 billion in 2023. The deal also added other rare ...